Search Result

Isoforms Recommended:	Aurora A

Results for "

Aurora+A

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Aurora Kinase (32) AAK1 (1) Apoptosis (11) Bcr-Abl (1) c-Fms (2) c-Kit (1) c-Myc (1) CDK (5) Checkpoint Kinase (Chk) (2) Cyclin G-associated Kinase (GAK) (1) DNA/RNA Synthesis (1) E1/E2/E3 Enzyme (1) EGFR (1) FAK (1) FGFR (2) FLT3 (3) G Protein-coupled Receptor Kinase (GRK) (2) Glycosidase (1) Histone Methyltransferase (1) Ligands for E3 Ligase (1) Ligands for Target Protein for PROTAC (2) MASTL (1) Mitosis (1) MMP (1) Mps1 (1) PKC (2) Polo-like Kinase (PLK) (1) PROTACs (5) Reference Standards (2) RET (2) Ser/Thr Protease (1) Small Interfering RNA (siRNA) (1) Src (2) TAM Receptor (1) Tie (1) VEGFR (3)
By Research Areas:	Cancer (32) Cardiovascular Disease (1) Metabolic Disease (1) Neurological Disease (1)
Oligonucleotides:	Mouse Pre-designed siRNA Sets (1) siRNAs (1)

Inhibitors & Agonists

Natural
Products

Recombinant Proteins

Antibodies

Oligonucleotides

Targets Recommended: Aurora Kinase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-114258

LY3295668 3 Publications Verification AK-01	Aurora Kinase Apoptosis	Cancer
LY3295668 (AK-01) is a highly specific and orally active inhibitor of Aurora-A kinase with a K_i values for AurA and AurB of 0.8 nM and 1038 nM respectively. LY3295668 can effectively inhibit the autophosphorylation of AurA, induce mitotic arrest and apoptosis. LY3295668 avoids the formation of polyploids related to AurB inhibition. LY3295668 can be used for the study of small cell lung cancer .

HY-10329

JNJ-7706621 5 Publications Verification	Aurora Kinase CDK Apoptosis	Cancer
JNJ-7706621 is a potent aurora kinase inhibitor, and also inhibits CDK1 and CDK2, with IC₅₀s of 9 nM, 3 nM, 11 nM, and 15 nM for CDK1, CDK2, *aurora-A* and *aurora-B*, respectively .

HY-10032

PF 477736 4 Publications Verification PF 00477736	Checkpoint Kinase (Chk) VEGFR Src c-Fms Aurora Kinase FGFR FLT3 RET CDK	Cancer
PF 477736 (PF 00477736) is a potent, selective and ATP-competitive inhibitor of Chk1, with a K_i of 0.49 nM, it is also a Chk2 inhibitor, with a K_i of 47 nM. PF 477736 shows <100-fold selectivity for Chk1 over VEGFR2, Fms, Yes, *Aurora-A, FGFR3, Flt3, and Ret* (IC₅₀=8 (K_i), 10, 14, 23, 23, 25, and 39 nM, respectively). PF 477736 can enhance Gemcitabine antitumor activity in vitro and in vivo .

HY-156863

GRK2 Inhibitor 2 1 Publications Verification	Aurora Kinase G Protein-coupled Receptor Kinase (GRK)	Cardiovascular Disease
GRK2 Inhibitor 2 is an orally active and selective G protein-coupled receptor kinase 2 (GRK) inhibitor with an IC₅₀ of 19 nM. GRK2 Inhibitor 2 also inhibits *Aurora-A* with an IC₅₀ of 137 nM. GRK2 Inhibitor 2 can be used in the study of congestive heart failure (HF) .

HY-N0419

Quercimeritrin 2 Publications Verification Quercetin-7-O-β-D-glucopyranoside	Glycosidase c-Kit MMP VEGFR Aurora Kinase	Metabolic Disease Cancer
Quercimeritrin (Quercetin-7-O-β-D-glucopyranoside) is an orally active α-glucosidase inhibitor (with an IC₅₀ of 79.88 μM against the Saccharomyces cerevisiae enzyme) and a P-gp substrate, with anti-angiogenic and antioxidant activities. Quercimeritrin does not cross the blood-brain barrier and does not inhibit cytochrome P450 enzymes. Quercimeritrin precisely binds to and inhibits the active sites of c-Kit, MMP-2, Aurora-A kinases and α-glucosidase, thereby disrupting target functions. Quercimeritrin effectively regulates postprandial blood glucose and also exhibits significant anti-angiogenic activity, which inhibits endothelial cell proliferation and microvascular growth. Quercimeritrin can be used in the research of diabetes and breast cancer .

HY-141512

JB170 3 Publications Verification	PROTACs Aurora Kinase	Cancer
JB170 is a potent and highly specific PROTAC-mediated *AURORA-A* (Aurora Kinase) degrader (DC₅₀=28 nM) by linking Alisertib, to the Cereblon-binding molecule Thalidomide. JB170 preferentially binds AURORA-A (EC₅₀=193 nM) over AURORA-B (EC₅₀=1.4 µM). JB170-mediated S-phase arrest is caused specifically by AURORA-A depletion. JB170 has excellent ability to inhibit non-catalytic function of AURORA-A kinase .

HY-142817

*GRK6/Aurora A-IN-1* 3 Publications Verification	G Protein-coupled Receptor Kinase (GRK) Aurora Kinase	Cancer
GRK6/Aurora A-IN-1 is a dual inhibitor of G protein-coupled receptor kinase 6 (GRK6)/Aurora A, with IC₅₀ values of 120 nM and 11 nM, respectively. GRK6 is a key kinase required for the survival of multiple myeloma (MM) cells. GRK6-IN-2 has the potential for research on multiple myeloma .

HY-18161

CCT241736	FLT3 Aurora Kinase	Cancer
CCT241736 is a potent and orally bioavailable dual FLT3 and Aurora kinase inhibitor, which inhibits Aurora kinases (Aurora-A K_d, 7.5 nM, IC₅₀, 38 nM; Aurora-B K_d, 48 nM), FLT3 kinase (K_d, 6.2 nM), and FLT3 mutants including FLT3-ITD (K_d, 38 nM) and FLT3(D835Y) (K_d, 14 nM).

HY-168439

HLB-0532259	PROTACs Aurora Kinase	Cancer
HLB-0532259 is a PROTAC degrader for *Aurora-A* and N-Myc. HLB-0532259 degrades *Aurora-Ain a non-MYCN amplified MCF-7 with a DC₅₀* of 20.2 nM, degrades N-Myc in MYCN amplified cells SK-N-BE and Kelly with DC₅₀ of 179 nM and 229 nM. HLB-0532259 exhibits antitumor efficacy in mouse models . (Pink: ligand for target protein (HY-168440); Black: linker (HY-W007957); Blue: ligand for E3 ligase Cereblon (HY-41547))

HY-171770

dAurAB5	PROTACs Aurora Kinase AAK1 Cyclin G-associated Kinase (GAK) Mps1 FAK	Cancer
dAurAB5 is a dual *Aurora-A* (DC₅₀ = 8.8 nM) and *Aurora-B* (DC₅₀ = 6.1 nM) PROTAC degrader. dAurAB5 induces degradation of *Aurora-A* and *Aurora-B*, reduces N-Myc levels, and decreases viability in IMR32 neuroblastoma cells. dAurAB5 downregulates the levels of AAK1, PTK2, GAK, and TTK. dAurAB5 can be used to study cancers such as neuroblastoma. (Pink: TTK ligand 2: HY-168542, Blue: Thalidomide-O-COOH: HY-103597, Black: 6-Aminocaproic acid: HY-B0236) .

HY-168440

Aurora-A ligand 1	Ligands for Target Protein for PROTAC Aurora Kinase CDK	Cancer
Aurora-A ligand 1 is a high-affinity and specific *Aurora-A* inhibitor with a dissociation constant (K_d) value of 0.85 nM. Aurora-A ligand 1 can serve as a ligand for target protein (Ligands for Target Protein for PROTAC) for the development of PROTAC Aurora-A degraders with antitumor activity. Aurora-A ligand 1 can be used for the synthesis of HLB-0532259 (HY-168439). HLB-0532259 shows anti-tumor activity against neuroblastoma .

HY-171769

dAurAB2	PROTACs Aurora Kinase	Cancer
dAurAB2 is a dual-degrading PROTAC that potently degrades *Aurora-A* and *Aurora-B* with DC₅₀s of 59 nM and 39 nM, respectively. dAurAB2 reduces N-Myc levels in MYCN-amplified IMR32 neuroblastoma cells. dAurAB2 can be used for the study of neuroblastoma. (Pink, Aurora ligand (HY-10804); Blue, E3 ligand: (HY-103597); Black, linker (HY-W105740)) .

HY-126249

AAPK-25	Aurora Kinase Polo-like Kinase (PLK) Apoptosis	Cancer
AAPK-25 is a potent and selective *Aurora/PLK* dual inhibitor with anti-tumor activity, which can cause mitotic delay and arrest cells in a prometaphase, reflecting by the biomarker histone H3 ^Ser10 phosphorylation and followed by a surge in apoptosis. AAPK-25 targets Aurora-A, -B, and -C with K_d values ranging from 23-289 nM, as well as PLK-1, -2, and -3 with K_d values ranging from 55-456 nM .

HY-W231513

*MASTL/Aurora A-IN-1*	MASTL Ser/Thr Protease Aurora Kinase	Cancer
MASTL/Aurora A-IN-1 (Compound MA4) is a dual inhibitor of MASTL and Aurora A kinases with IC₅₀ values of 0.56 μM and 0.16 μM, respectively. MASTL/Aurora A-IN-1 has broad-spectrum anticancer activity and has potent anticancer activity against SR (leukemia), K-562 (leukemia), MDA-MB-435 (melanoma), MOLT-4 (leukemia), and SK-MEL-2 (melanoma) cell lines in NCI-60 cancer cell lines with GI₅₀ values of 0.023, 0.032, 0.037, 0.044, and 0.051 μM, respectively. MASTL/Aurora A-IN-1 inhibits Aurora A and MASTL kinases, inducing cell cycle G2/M arrest, thereby inhibiting cancer cell proliferation. MASTL/Aurora A-IN-1 can be used in cancer research, especially for tumors with dysregulated mitosis .

HY-12564

Phthalazinone pyrazole	Aurora Kinase Apoptosis Mitosis	Cancer
Phthalazinone pyrazole is a potent, selective, and orally active inhibitor of Aurora-A kinase with an IC₅₀ of 0.031 μM. Phthalazinone pyrazole can arrests mitosis and subsequently inhibit tumor growth via apoptosis of proliferating cells. Phthalazinone pyrazole suppresses the epithelial-mesenchymal transition (EMT) during the differentiation of hepatocyte-like cells (HLCs) from human embryonic stem cells .

HY-178343

Aurora A-IN-5	Aurora Kinase Apoptosis	Cancer
Aurora A-IN-5 is a potent and highly selective Aurora A inhibitor (IC₅₀ = 0.02 μM), showing 362-fold selectivity for over Aurora B. Aurora A-IN-5 shows its selectivity through unique C−H/π interactions, enhanced hydrophobic contacts, an open binding pocket, and tighter protein packing. Aurora A-IN-5 suppresses Aurora A autophosphorylation, thereby inhibiting cancer cell proliferation by inducing G2/M phase arrest, triggering apoptosis, and suppressing colony formation. Aurora A-IN-5 inhibits tumor growth in MDA-MB-231 xenograft mouse models. Aurora A-IN-5 can be used for breast, cervical, prostate, and lymphoma cancer research .

HY-N3634

Corylifol C	EGFR TAM Receptor Tie	Cancer
Corylifol C is a potent protein kinase inhibitor with IC₅₀ valueS of 8.7, 3.0, 2.1, 6.4, 4.5, 6.2, 2.3, 1.2, 5.1 μg/ml for ARK5, Aurora-A, Aurora-B, AXL, B-RAF-VE, CDK4/CycD1, TIE2, EGF-R, EPHB4, respectively .

HY-125090

PHA-680626	Aurora Kinase c-Myc Bcr-Abl Histone Methyltransferase Apoptosis	Cancer
PHA-680626 is an effective inhibitor of the interaction between *Aurora-A* and N-Myc. PHA-680626 inhibits kinase activity of AURKA and Bcr-Abl, and induces N-Myc degradation. PHA-680626 decreases phosphorylation of CrkL and histone H3. PHA-680626 shows anti-proliferative and pro-apoptotic activity on Imatinib (HY-15463)-resistant chronic myeloid leukemia cell lines and primary CD34+ cells .

HY-156378

Aurora A inhibitor 3	Aurora Kinase	Cancer
Aurora A inhibitor 3 (Compound 5h) inhibits Aurora-A kinase with an IC₅₀ value of 0.78 μM. Aurora A inhibitor 3 is cytotoxic, with GI₅₀ values of 0.12 μM and 0.63 μM for MCF-7 and MDA-MB-231 cells, respectively .

HY-179643

Aurora-A ligand 2	Ligands for Target Protein for PROTAC Aurora Kinase	Cancer
Aurora-A ligand 2 is a ligand for the target protein of PROTAC. Aurora-A ligand 2 can be used to synthesize SK4454 (HY-179640) .

HY-144307

Aurora A/PKC-IN-1	Aurora Kinase PKC	Cancer
Aurora A/PKC-IN-1 (Compound 2e) is a potent dual inhibitor of Aurora A (AurA) and PKC (α, β1, β2, and θ) kinases with IC₅₀s of 6.9 nM and 16.9 nM for AurA and PKCα, respectively. Aurora A/PKC-IN-1 has antiproliferative activity in breast cancer cells and antimetastatic activity .

HY-146037

Aurora A inhibitor 2	Apoptosis Aurora Kinase	Cancer
Aurora A inhibitor 2 (Compound 16h) is a potent Aurora A kinase inhibitor with an IC₅₀ of 21.94 nM. Aurora A inhibitor 2 induces caspase-dependent apoptosis in MDA-MB-231 cells .

HY-167114

*(Rac)-Aurora A/PKC-IN-1*	Aurora Kinase PKC	Cancer
(Rac)-Aurora A/PKC-IN-1 (Compund 2e) is an orally active Aurora A and PKC (α, β1, β2 and θ) kinase inhibitor. (Rac)-Aurora A/PKC-IN-1 has antiproliferative activity in breast cancer cells in vitro and antimetastatic activity in vivo .

HY-143713

Aurora A inhibitor 1	Aurora Kinase	Cancer
Aurora A inhibitor 1 is a potent and selective inhibitor of Aurora A. Aurora A has been implicated in cancers of diverse histological origin and may possess oncogenic properties when overexpressed. Aurora A inhibitor 1 has the potential for the research of cancer diseases mediated by aurora a (extracted from patent WO2021147974A1, compound 49) .

HY-169735

Aurora A inhibitor 4	Aurora Kinase	Cancer
Aurora A inhibitor 4 (compound C9) is a potent inhibitor of Aurora A, with the GI₅₀ of 4.26 and 7.08 μM in DU 145 cells and HT-29 cells, respectively .

HY-N1168

Tenacigenin B	Aurora Kinase	Cancer
Tenacigenin B is a steroid that can be isolated from the genus Alocasia. Tenacigenin B has anti-tumor effects on lymphoma via regulation of *Aurora-A* .

HY-RS01267

Aurka Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Aurora Kinase	Others
Aurka Mouse Pre-designed siRNA Set A contains three designed siRNAs for Aurka gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Aurka Mouse Pre-designed siRNA Set A Aurka Mouse Pre-designed siRNA Set A

HY-N12436

11α-O-Tigloyl-12β-O-acetyltenacigenin B	Aurora Kinase	Cancer
11α-O-Tigloyl-12β-O-acetyltenacigenin B is an ester derivative of Tenacigenin B (HY-N1168), which is isolated from Garcinia cambogia (MTC). Tenacigenin B modulates the antitumor effects of Aurora-A in lymphoma.

HY-178517

Thalidomide-C1-O-CO-C11	E1/E2/E3 Enzyme Ligands for E3 Ligase	Cancer
Thalidomide-C1-O-CO-C11 is a ligand for E3 ubiquitin ligase. Thalidomide-C1-O-CO-C11 can be connected to Aurora-A ligand 1 (HY-168440) by a linker (HY-178512) to form PROTAC CDK4/6/9 degrader 2 (HY-178516) .

HY-181568

*PROTAC Aurora A* Degrader-1**	PROTACs Aurora Kinase DNA/RNA Synthesis Apoptosis	Neurological Disease Cancer
PROTAC Aurora A Degrader-1 (Compound 280) is a blood-brain barrier-permeable selective Aurora A PROTAC degrader, with DC₅₀ values of 1 nM and 2 nM in LAN5 and SMS-SAN cells, respectively. PROTAC Aurora A Degrader-1 induces the formation of a ternary complex between AURKA and CRBN, degrades AURKA, reduces MYCN levels, induces DNA damage and apoptosis, exerts antiproliferative activity in cancer cells, and regulates the immune system. PROTAC Aurora A Degrader-1 is applicable to the research of neuroblastoma and small cell lung cancer .

HY-183102

ATC12	Aurora Kinase Apoptosis	Cancer
ATC12 is a *Aurora-A* kinase inhibitor. ATC12 binds to *Aurora-A* and competes with TPX2 for binding to disrupt the *Aurora-A/TPX2* interaction. ATC12 inhibits cancer cell proliferation, induces apoptosis and cellular senescence. ATC12 can be used in the research of breast cancer .

HY-10329R

JNJ-7706621 (Standard)	Reference Standards Aurora Kinase CDK Apoptosis	Cancer
JNJ-7706621 (Standard) is the analytical standard of JNJ-7706621 (HY-10329). This product is intended for research and analytical applications. JNJ-7706621 is a potent aurora kinase inhibitor, and also inhibits CDK1 and CDK2, with IC₅₀s of 9 nM, 3 nM, 11 nM, and 15 nM for CDK1, CDK2, aurora-A and aurora-B, respectively .

HY-114258A

LY3295668 erbumine AK-01 erbumine	Aurora Kinase Apoptosis	Cancer
LY3295668 (AK-01) erbumine is a highly specific and orally active inhibitor of Aurora-A kinase with a K_i values for AurA and AurB of 0.8 nM and 1038 nM respectively. LY3295668 erbumine can effectively inhibit the autophosphorylation of AurA, induce mitotic arrest and apoptosis. LY3295668 erbumine avoids the formation of polyploids related to AurB inhibition. LY3295668 erbumine can be used for the study of small cell lung cancer .

HY-10032R

PF 477736 (Standard) PF 00477736 (Standard)	Checkpoint Kinase (Chk) Reference Standards VEGFR Src c-Fms Aurora Kinase FGFR FLT3 RET CDK	Cancer
PF 477736 (Standard) is the analytical standard of PF 477736 (HY-10032). This product is intended for research and analytical applications. PF 477736 (PF 00477736) is a potent, selective and ATP-competitive inhibitor of Chk1, with a Ki of 0.49 nM, it is also a Chk2 inhibitor, with a Ki of 47 nM. PF 477736 shows <100-fold selectivity for Chk1 over VEGFR2, Fms, Yes, Aurora-A, FGFR3, Flt3, and Ret (IC50=8 (Ki), 10, 14, 23, 23, 25, and 39 nM, respectively). PF 477736 can enhance Gemcitabine antitumor activity in vitro and in vivo .

Quercimeritrin 2 Publications Verification Quercetin-7-O-β-D-glucopyranoside	Flavonols Structural Classification Ginkgoaceae Classification of Application Fields Metabolic Disease Plants Compositae Endogenous metabolite Ginkgo biloba Human Gut Microbiota Metabolites Flavonoids Derris scandens Disease Research Fields Source Classification	Glycosidase c-Kit MMP VEGFR Aurora Kinase
Quercimeritrin (Quercetin-7-O-β-D-glucopyranoside) is an orally active α-glucosidase inhibitor (with an IC₅₀ of 79.88 μM against the Saccharomyces cerevisiae enzyme) and a P-gp substrate, with anti-angiogenic and antioxidant activities. Quercimeritrin does not cross the blood-brain barrier and does not inhibit cytochrome P450 enzymes. Quercimeritrin precisely binds to and inhibits the active sites of c-Kit, MMP-2, Aurora-A kinases and α-glucosidase, thereby disrupting target functions. Quercimeritrin effectively regulates postprandial blood glucose and also exhibits significant anti-angiogenic activity, which inhibits endothelial cell proliferation and microvascular growth. Quercimeritrin can be used in the research of diabetes and breast cancer .

Corylifol C	Leguminosae Phenols Polyphenols Psoralea corylifolia L. Plants Source Classification	EGFR TAM Receptor Tie
Corylifol C is a potent protein kinase inhibitor with IC₅₀ valueS of 8.7, 3.0, 2.1, 6.4, 4.5, 6.2, 2.3, 1.2, 5.1 μg/ml for ARK5, Aurora-A, Aurora-B, AXL, B-RAF-VE, CDK4/CycD1, TIE2, EGF-R, EPHB4, respectively .

Tenacigenin B	Araceae Cardiacglycosides Plants Alocasia cucullata (Lour.) Schott Steroids Source Classification	Aurora Kinase
Tenacigenin B is a steroid that can be isolated from the genus Alocasia. Tenacigenin B has anti-tumor effects on lymphoma via regulation of *Aurora-A* .

11α-O-Tigloyl-12β-O-acetyltenacigenin B	Structural Classification Marsdenia tenacissima (Roxb.) Moon Asclepiadaceae Plants Steroids Source Classification	Aurora Kinase
11α-O-Tigloyl-12β-O-acetyltenacigenin B is an ester derivative of Tenacigenin B (HY-N1168), which is isolated from Garcinia cambogia (MTC). Tenacigenin B modulates the antitumor effects of Aurora-A in lymphoma.

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P701706

	AURKA Protein, Human (Inactive, sf9) AURKA; Aurora kinase A; Aurora 2; Aurora/IPL1-related kinase 1; ARK-1; Aurora-related kinase 1; hARK1; Breast tumor-amplified kinase; Serine/threonine-protein kinase 15; Serine/threonine-protein kinase 6; Serine/threonine-protein kinase aurora-A	Human	Sf9 insect cells

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Host:	Mouse (4) Rabbit (2)
Reactivity:	Human (6) Rat (3) Mouse (3) Monkey (4)
Application:	IHC-P (2) ICC/IF (6) IP (1) WB (6) FC (3) ELISA (3)
Isotype:	IgG (1) IgG1 (4)
Conjugation:	Non-conjugated (6)
Clonality:	Monoclonal (3) Monoclonal Antibody (1) Recombinant (1)
Modification:	Unmodified (4)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P80971

	Aurora A Antibody (YA859) Aurora A	WB, ICC/IF, IHC-P, FC	Human, Mouse, Rat
	Aurora A Antibody (YA859) is a Rabbit-derived and non-conjugated monoclonal antibody, targeting to Aurora A.

HY-P80561

	Aurora A Antibody (YA827) AIK; ARK1; AYK1; Aurora-A; Aurora-related kinase 1; BTAK; IAK1; Ipl1- and aurora-related kinase 1; STK15; STK6; Serine/threonine kinase 15	WB, ICC/IF	Human, Monkey
	Aurora A Antibody (YA827) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Aurora A.

HY-P80561A

	Aurora A Antibody (YA827)(PBS only) AIK; ARK1; AYK1; Aurora-A; Aurora-related kinase 1; BTAK; IAK1; Ipl1- and aurora-related kinase 1; STK15; STK6; Serine/threonine kinase 15	WB, ICC/IF	Human, Monkey
	Aurora A Antibody (YA827) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Aurora A.

HY-P86641

	Aurora A Antibody (YA6333) Aurora kinase A; Aurora 2; Aurora/IPL1-related kinase 1; ARK-1; Aurora-related kinase 1; hARK1; Breast tumor-amplified kinase; Serine/threonine-protein kinase 15; Serine/threonine-protein kinase 6; Serine/threonine-protein kinase aurora-A;	WB, IHC-P, ICC/IF, IP, ELISA	Human
	Aurora A Antibody (YA6333) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Aurora A.

HY-P83819

	Aurora A Antibody (YA3516) AIK; ARK1; AURA; BTAK; STK6; STK7; STK15; AURORA2; MGC34538; AURKA	WB, ICC/IF, FC, ELISA	Human, Mouse, Rat, Monkey
	Aurora A Antibody (YA3516) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Aurora A.

HY-P83819A

	Aurora A Antibody (YA3516)(PBS only) AIK; ARK1; AURA; BTAK; STK6; STK7; STK15; AURORA2; MGC34538; AURKA	WB, ICC/IF, FC, ELISA	Human, Mouse, Rat, Monkey
	Aurora A Antibody (YA3516) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Aurora A.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks